Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

33 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Glucagon-like peptide-1 receptor agonists or sodium-glucose cotransporter-2 inhibitors as add-on therapy for patients with type 2 diabetes? A systematic review and meta-analysis of surrogate metabolic endpoints.
Patoulias D, Katsimardou A, Kalogirou MS, Zografou I, Toumpourleka M, Imprialos K, Stavropoulos K, Stergiou I, Papadopoulos C, Doumas M. Patoulias D, et al. Among authors: zografou i. Diabetes Metab. 2020 Sep;46(4):272-279. doi: 10.1016/j.diabet.2020.04.001. Epub 2020 May 8. Diabetes Metab. 2020. PMID: 32437914
The potential role of statins in treating liver disease.
Imprialos KP, Stavropoulos K, Doumas M, Skalkou A, Zografou I, Athyros VG. Imprialos KP, et al. Among authors: zografou i. Expert Rev Gastroenterol Hepatol. 2018 Apr;12(4):331-339. doi: 10.1080/17474124.2018.1439379. Epub 2018 Feb 12. Expert Rev Gastroenterol Hepatol. 2018. PMID: 29431526 Review.
Glycemic efficacy and safety of glucagon-like peptide-1 receptor agonist on top of sodium-glucose co-transporter-2 inhibitor treatment compared to sodium-glucose co-transporter-2 inhibitor alone: A systematic review and meta-analysis of randomized controlled trials.
Patoulias D, Stavropoulos K, Imprialos K, Katsimardou A, Kalogirou MS, Koutsampasopoulos K, Zografou I, Papadopoulos C, Karagiannis A, Doumas M. Patoulias D, et al. Among authors: zografou i. Diabetes Res Clin Pract. 2019 Dec;158:107927. doi: 10.1016/j.diabres.2019.107927. Epub 2019 Nov 13. Diabetes Res Clin Pract. 2019. PMID: 31733280
Prognostic value of arterial stiffness measurements in cardiovascular disease, diabetes, and its complications: The potential role of sodium-glucose co-transporter-2 inhibitors.
Patoulias D, Papadopoulos C, Stavropoulos K, Zografou I, Doumas M, Karagiannis A. Patoulias D, et al. Among authors: zografou i. J Clin Hypertens (Greenwich). 2020 Apr;22(4):562-571. doi: 10.1111/jch.13831. Epub 2020 Feb 14. J Clin Hypertens (Greenwich). 2020. PMID: 32058679 Free PMC article. Review.
Dapagliflozin decreases ambulatory central blood pressure and pulse wave velocity in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled clinical trial.
Papadopoulou E, Loutradis C, Tzatzagou G, Kotsa K, Zografou I, Minopoulou I, Theodorakopoulou MP, Tsapas A, Karagiannis A, Sarafidis P. Papadopoulou E, et al. Among authors: zografou i. J Hypertens. 2021 Apr 1;39(4):749-758. doi: 10.1097/HJH.0000000000002690. J Hypertens. 2021. PMID: 33186325 Clinical Trial.
Effects of long-term use of sodium-glucose co-transporter-2 inhibitors on plasma volume status in patients with type 2 diabetes mellitus: Sub-analysis of a prospective, observational study during the COVID-19 pandemic.
Patoulias D, Papadopoulos C, Zografou I, Katsimardou A, Imprialos K, Stavropoulos K, Tranidou A, Karagiannis A, Doumas M. Patoulias D, et al. Among authors: zografou i. Kardiol Pol. 2022;80(1):80-82. doi: 10.33963/KP.a2021.0160. Epub 2021 Nov 16. Kardiol Pol. 2022. PMID: 34783355 Free article. No abstract available.
33 results